We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+1.66%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.45B
AUM Growth
+$98.6M
Cap. Flow
+$39.6M
Cap. Flow %
1.62%
Top 10 Hldgs %
39.51%
Holding
166
New
25
Increased
26
Reduced
19
Closed
10

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$38M
2
COR icon
Cencora
COR
+$30.2M
3
CVS icon
CVS Health
CVS
+$22.3M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$21M
5
GILD icon
Gilead Sciences
GILD
+$16M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$36M
2
MDVN
MEDIVATION, INC.
MDVN
+$23.3M
3
NVO
Novo Nordisk
NVO
+$16M
4
VTR icon
Ventas
VTR
+$14.3M
5
DOC
PHYSICIANS REALTY TRUST
DOC
+$13.4M

Sector Composition

Rank Sector Weight
1 Healthcare 86.46%
2 Real Estate 2.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARDX icon
51
Ardelyx
ARDX
$1.25B
$12.1M 0.5%
1,389,370
– –
ACAD icon
52
Acadia Pharmaceuticals
ACAD
$4.55B
$11.8M 0.48%
363,585
-351,714
-49% -$11.8M
DOC
53
DELISTED
PHYSICIANS REALTY TRUST
DOC
$11.1M 0.46%
530,672
-700,100
-57% -$13.4M
VTR icon
54
Ventas
VTR
$44.7B
$11.1M 0.45%
152,491
-216,775
-59% -$14.3M
EXEL icon
55
Exelixis
EXEL
$14.1B
$11M 0.45%
1,405,420
– –
NTRA icon
56
Natera
NTRA
$38.6B
$10.6M 0.43%
882,358
– –
PRTK
57
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$10.6M 0.43%
762,581
– –
CPHD
58
DELISTED
Cepheid Inc
CPHD
$10.3M 0.42%
333,590
– –
UTHR icon
59
United Therapeutics
UTHR
$26.2B
$9.86M 0.4%
93,100
– –
SBRA icon
60
Sabra Healthcare REIT
SBRA
$5.38B
$9.41M 0.38%
456,190
– –
HRTX icon
61
Heron Therapeutics
HRTX
$94.1M
$8.89M 0.36%
492,303
+273,303
+125% +$5.34M
CNC icon
62
Centene
CNC
$30.1B
$8.56M 0.35%
240,000
– –
CLLS
63
Cellectis
CLLS
$287M
$8.25M 0.34%
310,250
– –
LKFT
64
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$8.2M 0.33%
147,738
+127,738
+639% +$6.42M
PBYI icon
65
Puma Biotechnology
PBYI
$402M
$7.75M 0.32%
260,200
– –
CTMX icon
66
CytomX Therapeutics
CTMX
$714M
$7.72M 0.32%
756,090
+428,031
+130% +$4.88M
CYNA
67
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$7.71M 0.31%
460,207
+279,800
+155% +$3.77M
ITCI
68
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$7.29M 0.3%
187,800
– –
WMGI
69
DELISTED
Wright Medical Group Inc
WMGI
$7M 0.29%
+402,950
New +$7.39M
JUNO
70
DELISTED
Juno Therapeutics, Inc.
JUNO
$7M 0.29%
182,000
– –
AKRX
71
DELISTED
Akorn Inc
AKRX
$6.99M 0.29%
245,235
– –
ELGX
72
DELISTED
Endologix Inc
ELGX
$6.87M 0.28%
55,100
– –
AVDL
73
DELISTED
Avadel Pharmaceuticals
AVDL
$6.71M 0.27%
624,288
– –
PVLA
74
Palvella Therapeutics
PVLA
$2.15B
$6.2M 0.25%
48,102
– –
FOMX
75
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$6.13M 0.25%
966,065
– –
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2016 Portfolio in Review

As of Q2 2016, Tekla Capital Management held 166 positions worth $2.45B, up 4.2% from $2.35B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management's Q2 2016 filing shows 25 new, 26 increased, 19 reduced and 10 closed positions. Its largest new stake was Abbott: 953,500 shares worth $37.5M. The largest sale was Celgene Corp, an estimated $36M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 87% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2016 buy was Abbott: 953,500 shares worth $37.5M.
  • Tekla Capital Management added most to Neurocrine Biosciences in Q2 2016, an estimated $21M increase.
  • Tekla Capital Management's biggest Q2 2016 reduction was Celgene Corp, cutting an estimated $36M.
  • Tekla Capital Management fully exited Novo Nordisk in Q2 2016, selling an estimated $16M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.45B portfolio in Q2 2016.
  • Tekla Capital Management opened 25 new positions and closed 10 in Q2 2016.
  • Tekla Capital Management's portfolio value rose 4.2% quarter-over-quarter to $2.45B.

Based on Tekla Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.